DECTOVA

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug DECTOVA contains one active pharmaceutical ingredient (API):

1	Zanamivir UNII L6O3XI777I - ZANAMIVIR
	Zanamivir is an inhibitor of influenza virus neuraminidase, an enzyme that releases viral particles from the plasma membrane of infected cells and promotes virus spread in the respiratory tract. The activity of zanamivir is extracellular. It reduces the propagation of both influenza A and B viruses by inhibiting the release of infectious influenza virions from the epithelial cells of the respiratory tract.
	Read more about Zanamivir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DECTOVA Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AH01	Zanamivir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AH Neuraminidase inhibitors
Discover more medicines within J05AH01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1795754, 1874246
FI	Lääkealan turvallisuus- ja kehittämiskeskus	395010
FR	Base de données publique des médicaments	64427189
GB	Medicines & Healthcare Products Regulatory Agency	378891
LT	Valstybinė vaistų kontrolės tarnyba	1087663
NL	Z-Index G-Standaard, PRK	199818
PL	Rejestru Produktów Leczniczych	100420087